Mesalazine-induced myopericarditis: a case series

Eur Heart J Case Rep. 2023 Sep 1;7(9):ytad424. doi: 10.1093/ehjcr/ytad424. eCollection 2023 Sep.

Abstract

Background: Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the gastrointestinal tract but can have multiorgan involvement. Mesalazine (5-ASA) is a key therapeutic agent in IBD. Mesalazine has rare but potentially life-threatening side effects such as cardiac injury.

Case summary: We present two cases of myopericarditis, documented also with cardiac magnetic resonance, that we attributed to 5-ASA hypersensitivity: the first is a young woman with ulcerative colitis who developed myopericarditis after the initiation of 5-ASA, with a good clinical response after discontinuation; the second is a 79-year-old man who developed symptoms of heart failure after the diagnosis of IBD and the introduction of 5-ASA.

Discussion: Mesalazine may cause rare but potentially life-threatening cardiac injury, which can be difficult to distinguish from acute IBD-induced cardiac inflammation.

Keywords: 5-ASA; Cardiotoxicity; Case series; Inflammatory bowel diseases; Mesalazine; Myopericarditis.

Publication types

  • Case Reports